Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA), on behalf of the Department of Defense (DoD), has issued a Request for Quotation (RFQ) for pharmaceutical agents to be considered for placement on the DoD Uniform Formulary (UF). This initiative aims to establish Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) Agreements to ensure effective and efficient pharmacy benefits for the Military Health System (MHS). Manufacturers are invited to submit price quotes for specific drug classes, including Antihemophilic Agents (Non-Factor Agents) and Leukemia and Lymphoma (BCR-ABL-TKI). Quotes are due by April 2, 2026, at 12:00 PM CST.
Scope of Work
This solicitation seeks to obtain quotes for pharmaceutical agents within drug classes identified for review by the DoD Pharmacy and Therapeutics (P&T) Committee. The goal is to select agents for the DoD UF and classify them for cost-sharing purposes (generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary). The resulting UF BPAs will cover prices for Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP), while UF ADPs will address refunds for agents dispensed by TRICARE retail network pharmacies.
Key Requirements
Manufacturers must submit price quotes for pharmaceutical agents, including all National Drug Code (NDC)-11 numbers, unless specific exclusions are approved. Pricing must be provided per unit of measure and per NDC-11 package. Quotes for UF BPAs must be valid for 180 days. UF ADP refund quotes are contingent upon the agent's placement on the UF. Bidders must utilize the provided BPA and ADP appendices, following instructions in the "NDC Price List FAQ" document.
Eligibility
Manufacturers must possess an existing Federal Supply Schedule (FSS) Contract Number or FSS Interim Agreement. Quotes for generic (multi-source) pharmaceutical agents will not be accepted if existing Joint DoD/Veterans Administration (VA) contracts are already in place.
Contract & Timeline
- Opportunity Type: Solicitation (RFQ)
- Product/Service Code: 6505 (Drugs And Biologicals)
- Set-Aside: None
- Published Date: January 28, 2026
- Pre-Quotation Teleconference: February 11, 2026, 1:00 PM CST
- Quotes Due: April 2, 2026, 12:00 PM CST
- P&T Committee Meeting: May 6-7, 2026
Evaluation
The DoD P&T Committee will evaluate pharmaceutical agents based on their relative clinical effectiveness and cost-effectiveness. This includes considering the submitted UF BPA price quotes and UF ADP refund quotes when recommending placement and cost-share tier classification for agents on the Uniform Formulary.
Submission Details
Bidders must download the Utilization Dataset and NDC Price List, complete the applicable pages and price appendices (Appendix 1 for all quotes; Appendix 2 for BPA quotes; Appendix 3 for ADP quotes), and submit signed quotes and the NDC Price List to the RFQ Point of Contact. A pre-quotation teleconference is scheduled to address industry questions, and one-on-one appointments with the Industry Technical Liaison are available.
Points of Contact
- Primary: Tracy Banks (tracy.e.banks2.civ@health.mil)
- Secondary: Kirk Heyen (kirk.e.heyen.ctr@health.mil)